News

Medianet News Hub
newshub. medianet. com. au > 2026 > 07 > australias-medical-and-science-industry-unites-to-raise-concerns-about-proposed-rd-tax-changes > 160413

Australia's medical and science industry unites to raise concerns about proposed R&D tax changes

1+ hour, 3+ min ago  (578+ words) Seventeen of Australia's leading medical industry and science organisations have written to the'Albanese Government to express serious concern with the Federal Budget's proposed changes to the R&D tax incentive (RDTI). Industry leaders across biotech, medtech, health tech, pharmaceuticals, science…...

Symbols: asx:org,asx:rio,asx:bhp
Endpoints News
endpoints. news > scribe-therapeutics-files-for-ipo-in-test-of-appetite-for-early-stage-biotechs

Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs

29+ min ago  (66+ words) Endpoints News Scribe Ther'a'peu'tics files for IPO in test of pub'lic ap'petite for ear'li'er-stage biotechs Scribe Ther'a'peu'tics filed for a Nas'daq IPO late Thurs'day. The move marks a piv'otal mo'ment for the biotech and the gene-edit'ing " Think we're worth reading…...

Symbols: nasdaq:pbls,nasdaq:atra
Crain's Chicago Business
chicagobusiness. com > health-care > ccb-abbvie-clinical-trials-china-congress-20260702

Abb Vie faces federal probe over drug trials in China

1+ hour, 25+ min ago  (38+ words) Crain's Chicago Business Abb Vie faces federal probe over drug trials in China These 14 families wield influence across Chicago and Illinois through business, politics, philanthropy, sports and civic institutions....

Symbols: nyse:abbv
Trading View
tradingview. com > news > tradingview: 7561c50cf6562: 0-pyxis-oncology-raises-50-million-in-private-placement-warrants-could-add-64-million

Pyxis Oncology Raises $50 Million in Private Placement; Warrants Could Add ~$64 Million

2+ hour, 26+ min ago  (213+ words) Trading View Pyxis Oncology Raises $50 Million in Private Placement; Warrants Could Add ~$64 Million Pyxis Oncology announced a financing through a private placement of 19, 600, 153 common shares at $2. 551 per share with accompanying common warrants, expected to yield approximately $50. 0 million in gross proceeds…...

Symbols: nasdaq:pyxs,nasdaq:elvn
Moomoo
moomoo. com > community > feed > merck-bristol-myers-squibb-are-key-partners-in-trials-executives-116850361958409

Merck & Bristol Myers Squibb are key partners in trials. Executives ready for company purchase!

10+ hour, 25+ min ago  (16+ words) Moomoo...

Symbols: nyse:bmy
Causeartist
causeartist. com > podcast > investing-in-impact > how-gross-labs-is-building-a-new-model-for-culture-capital-and-impact

How Gross Labs Combines Culture, Capital, and Impact

5+ hour, 1+ min ago  (1645+ words) Founder " Gross Labs Search for this company in the directory Nick Gross does not describe Gross Labs as a traditional family office. To him, it is a family enterprise and cultural investment platform, one designed to actively build businesses, support…...

Symbols: nasdaq:pfai
Streetwise Reports
streetwisereports. com > article > 07/02/2026 > abivax-sa-abvx-nasdaq-uc-data-fuels-biotech-opportunity. html

Abivax SA (ABVX: NASDAQ) UC Data Fuels Biotech Opportunity

3+ hour, 5+ min ago  (653+ words) Abivax SA (ABVX: NASDAQ) reports strong obefazimod maintenance results in ulcerative colitis. Explore sector growth, analyst targets, catalysts, and what it means for investors. The global market for ulcerative colitis treatments is projected to reach US$16. 5 billion by 2034, expanding at…...

Symbols: nasdaq:abvx
STAT
statnews. com > pharmalot > 07/02/2026 > pharma-biotech-jobs-ladder-vertex-gilead-astrazeneca-lilly

Up and down the ladder: The latest comings and goings

5+ hour, 17+ min ago  (118+ words) But all work and no play can make for a dull chief scientific officer. And here is our regular feature in which we highlight a different person each week. This time around, we note that'Protillion Biosciences hired Robert Hollingsworth as…...

Symbols: high-a,ticker:init
Food and Drink Technology
foodanddrinktechnology. com > news > 68334 > gea-consolidates-biotechnology-center-to-accelerate-commercial-scale-up

GEA consolidates biotechnology center to accelerate scale-up

3+ hour, 53+ min ago  (192+ words) GEA has announced a "4 million investment to relocate and expand its Application and Technology Center (ATC) for New Food and Biotechnology. Moving from its interim facility in Hildesheim to a permanent, consolidated hub in Sarstedt, Lower Saxony, the move unites…...

Symbols: npg-ag
Boston Globe. com
bostonglobe. com > 07/02/2026 > business > buyout-bluebird-bio-genetix

A year after distressed buyout, what's become of Somerville's Bluebird Bio?

22+ min ago  (890+ words) David Meek bought Somerville-based Bluebird Bio last year for the pharma industry equivalent of loose change. The company was on the brink of bankruptcy. In 12 months, he says, it's been transformed. In a swaggering interview, one of the first he's…...

Symbols: nasdaq:blbd